Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats.
Drug metabolism and disposition: the biological fate of chemicals·2003
Platelet factor V New York: a defect in factor V distinct from that in factor V Quebec resulting in impaired prothrombinase generation.
American journal of hematology·2001
Platelet IgG: measurement, interpretation, and clinical significance.
Progress in hemostasis and thrombosis·1991
The lipoprotein-associated coagulation inhibitor.
Progress in hemostasis and thrombosis·1991
Thrombospondin: phenomenology to function.
Progress in hemostasis and thrombosis·1989
Porcine von Willebrand disease: implications for the pathophysiology of atherosclerosis and thrombosis.
Progress in hemostasis and thrombosis·1986
Intravenous immunoglobulin therapy for the treatment of idiopathic thrombocytopenic purpura.
Progress in hemostasis and thrombosis·1986
Desmopressin (DDAVP) for treatment of disorders of hemostasis.
Progress in hemostasis and thrombosis·1986
Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals.
Handbook of experimental pharmacology·2026
Must RAAS-modifying drugs be withdrawn for the diagnosis of primary aldosteronism?
The Journal of clinical endocrinology and metabolism·2026
Combination Treatment of IL-17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review.
Immunity, inflammation and disease·2026